This site is intended for health professionals only

Pfizer halts lung cancer trial


Pfizer’s late-stage drugs pipeline has suffered another rupture with the news that the firm has terminated trials of an experimental lung cancer treatment.

The New York-based drugs giant said it has discontinued a development programme in advanced nonsmall-cell lung cancer for PF-3512676 in combination with cytotoxic chemotherapy. This includes two phase III and two phase III trials of the drug, previously called ProMune

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: